Overview
Atto Trading is a quantitative high-frequency trading firm. It uses research-driven methods to trade in financial markets, focusing on market microstructure, non-linear modeling, and high-performance software engineering. The company operates with a collaborative culture where researchers, engineers, and competitive programmers share tools and knowledge to develop scalable trading systems. Its approach combines speed and rigorous research rather than choosing one, aiming to turn deep understanding of how markets work into actionable strategies. The goal is to build and deploy analytic models and trading systems that consistently generate alpha across multiple asset classes, with ownership, merit-based recognition, and strong impact for the individuals who contribute.
Work here?Claim your company
Simplify's take
What believers are saying
- September 30, 2026 cash reached $395.9 million, funding operations into 2030.
- The August 2026 IPO raised $332.4 million gross, reducing near-term financing pressure.
- Phase 2 starts for ATTO-1310, ATTO-2306, and ATTO-1091 all target 1H 2027.
What critics are saying
- ATTO-1310 has only 26 patients per cohort; Phase 2 will expose weaker efficacy.
- No collaboration revenue in Q3 2026; commercialization depends entirely on clinical success.
- If ATTO-1310 fails Phase 2 in 2027, Attovia becomes a single-program public biotech.
What makes Atto Trading unique
- ATTO-1310 targets IL-31, a validated itch pathway with clear biomarker readouts.
- Attovia reported 95% IL-31 suppression and 82% chronic-pruritus response at Week 12.
- The company also has ATTO-2306 and ATTO-1091 advancing into 2027 trials.
Help us improve and share your feedback! Did you find this helpful?